Secondary Prevention Clinical Trials

6 recruiting

Secondary Prevention Trials at a Glance

10 actively recruiting trials for secondary prevention are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 6 trials, with the heaviest enrollment activity in Anyang, Bad Neustadt an der Saale, and Beijing. Lead sponsors running secondary prevention studies include Dacima Consulting, Haukeland University Hospital, and China National Center for Cardiovascular Diseases.

Browse secondary prevention trials by phase

Treatments under study

About Secondary Prevention Clinical Trials

Looking for clinical trials for Secondary Prevention? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Secondary Prevention trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Secondary Prevention clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients

Cardiovascular DiseasesAtherosclerotic Cardiovascular Disease (ASCVD)Secondary Prevention
Peking University First Hospital5,448 enrolled1 locationNCT07542860
Recruiting
Not Applicable

The Southern-Norway Post-Stroke Atrial Fibrillation Study

Atrial Fibrillation (AF)Ischemic StrokeAtrial Fibrillation (Prevention of Stroke)+2 more
Sorlandet Hospital HF450 enrolled1 locationNCT07407790
Recruiting
Not Applicable

Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients

Secondary Prevention of Coronary Heart Disease
China National Center for Cardiovascular Diseases200 enrolled1 locationNCT07259278
Recruiting
Not Applicable

SmartWatch-driven AF Detection in Stroke Patients

Atrial Fibrillation (AF)Ischemic StrokeSecondary Prevention+2 more
University of Leipzig80 enrolled13 locationsNCT06832579
Recruiting
Phase 2

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Primary/Secondary PreventionHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital1,076 enrolled1 locationNCT07187908
Recruiting

National Tunisian Clinical Registry on CardioVascular Secondary Prevention Clinical

Secondary PreventionCHDCV Risk
Dacima Consulting5,000 enrolled1 locationNCT07034274
Recruiting
Not Applicable

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

Cardiovascular DiseasesIschemic StrokeSmall Vessel Cerebrovascular Disease+2 more
Seoul National University Hospital4,016 enrolled46 locationsNCT06649240
Recruiting
Not Applicable

Electronic Cardiac Rehabilitation (eCardiacRehab) Feasibility Study

HypertensionPhysical ActivityWomen+13 more
Haukeland University Hospital80 enrolled1 locationNCT06759805
Recruiting
Not Applicable

A Pilot Study to Assess Optimal Prevention and Outcome Improvement in Young Ischemic Stroke

Secondary PreventionIschemic Stroke At a Young Age
IRCCS National Neurological Institute "C. Mondino" Foundation36 enrolled1 locationNCT06820411
Recruiting
Phase 4

Biomarker-guided Management Following a Heart Attack

Secondary prevention post-acute coronary syndromesCardiovascular Disease
Professor Rob Doughty1,028 enrolled1 locationACTRN12619001445167